Pharmasset receives fast track designation
Pharmasset, Inc. (Nasdaq: VRUS) reported this morning that it received fast track designation from the U.S. Food and Drug Administration for its prodrug R7128 for the treatment of chronic hepatitis C virus (HCV) infection.
Pharmasset is currently conducting a Phase 1 clinical trial to evaluate R7128 in combination with Pegasys and Copegus for treatment-naive patients chronically infected with hepatitis C virus (HCV) genotype 1.
R7128 is a prodrug of PSI-6130, which is an oral cytidine nucleoside analog polymerase inhibitor of HCV that Pharmasset is developing with Roche.
Shares of Pharmasset (VRUS) were halted in pre-market trading.
